Speakers
Adam J. Adler, Ph.D., Professor, Immunology, University of Connecticut
Prasad S. Adusumilli, M.D., FACS, Deputy Chief of Translational & Clinical, Research, Thoracic Surgery, Memorial Sloan-Kettering Cancer Center
Omar Ali, Ph.D., Staff Scientist, Wyss Institute for Biologically Inspired Engineering, Harvard University
Robert Anders, M.D., Ph.D., Associate Professor, Pathology, Johns Hopkins University
Philip M. Arlen, M.D., President & CEO, Precision Biologics, Inc.
Roy D. Baynes, M.D., Ph.D., Senior Vice President and Head, Global Clinical Development, Merck Research Laboratories
Stephen Beers, Ph.D., Associate Professor, Cancer Immunology and Immunotherapy, University of Southampton
John Bell, Ph.D., Senior Scientist, Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, Professor, Departments of Medicine and Biochemistry, Microbiology & Immunology, University of Ottawa
Kevin Bonham, Ph.D., Curriculum Fellow, Microbiology and Immunobiology Department, Harvard Medical School
Chris Boshoff, M.D., Ph.D., Vice President and Head, Early, Development, Translational and Immuno-Oncology, Pfizer
Adrian Bot, M.D., Ph.D., Vice President, Translational Sciences, R&D, Kite Pharma Inc.
Caroline Breitbach, Ph.D., Vice President, Translational Development, Turnstone Biologics
Joshua Brody, M.D., Director, Lymphoma Immunotherapy Program, Icahn School of Medicine at Mount Sinai
Tullia Bruno, Ph.D., Research Assistant Professor, Immunology, University of Pittsburgh
Manel Cascallo, Ph.D., Co-Founder, President and CEO, VCN Biosciences
Saso Cemerski, Ph.D., Associate Principal Scientist, Merck Research Laboratories
Edward Cha, M.D., Ph.D., Associate Medical Director, Cancer Immunotherapy Franchise, Genentech
Brian Champion, Ph.D., Senior Vice President, R&D, PsiOxus Therapeutics Ltd
Zhao Chen, Ph.D., Investigator III, Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research
Yeong “Christopher” Choi, Ph.D., Director, TCPF and Assistant Professor of Oncology, Center for Immunotherapy, Roswell Park Cancer Institute
Robert Coffin, Ph.D., CEO, Replimmune
Joe Conner, Ph.D., CSO, Virttu Biologics
Michael A. Curran, Ph.D., Assistant Professor, Immunology; Scientific Director, ORBIT Platform MD Anderson Cancer Center
Adil Daud, M.D., Professor, Hematology/Oncology, University of California, San Francisco; Director, Melanoma Clinical Research, UCSF Helen Diller Family Comprehensive Cancer Center
Anthony Davies, Ph.D., COO, 4D Molecular Therapeutics
John Desjarlais, Ph.D., CSO, Xencor
Luis Alberto Diaz, M.D., Associate Professor, Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Gianpietro Dotti, M.D., Professor, Microbiology and Immunology, University of North Carolina
Jakob Dupont, M.D., Senior Vice President & CMO, OncoMed Pharmaceuticals
Kenneth Emancipator, M.D., Executive Medical Director, Companion Diagnostics, Merck & Co.
Boris Engels, Ph.D., Investigator, Exploratory Immuno-Oncology, Novartis Institutes for Biomedical Research
Andrew M. Evens, D.O., Professor and Chief, Hematology/Oncology, Tufts University School of Medicine; Director, Tufts Cancer Center
Christopher R. Heery, M.D., Director, Clinical Trials Group, Laboratory of Tumor Immunology, Center for Cancer Research
Christian S. Hinrichs, MD, Investigator, Experimental Transplantation and Immunology Branch, Lasker Clinical Research Scholar, NIH
Mark J. Federspiel, Ph.D., Professor and Director, Viral Vector Production Laboratory, Mayo Clinic
Patrick Forde, M.D., Assistant Professor, Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Morganna Freeman, D.O., Medical Oncologist, Immunotherapeutics, The Angeles Clinic and Research Institute
Bruce Freimark, Ph.D., Research Director, Preclinical Oncology, Peregrine Pharmaceuticals
Jennifer Gansert, Ph.D., Executive Director, Global Development Lead, Amgen, Inc.
Sanja Gauthier, M.D., Senior Medical Director, Medical Safety Evaluation, Pharmacovigilance and Patient Safety, AbbVie
Tariq Ghayur, Ph.D., Distinguished Research Fellow, AbbVie Bioresearch Center
Geoffrey T. Gibney, M.D., Medical Oncologist, Georgetown-Lombardi Comprehensive Cancer Center
Sacha Gnjatic, Ph.D., Associate Professor, Tisch Cancer Institute, Hematology/Oncology, Immunology, Icahn School of Medicine at Mount Sinai
Matthew J. Goldstein, M.D., Ph.D., Director, Translational Medicine, Neon Therapeutics, Inc.
Jeffrey Hanke, Ph.D., CSO, Tesaro
Ronald Herbst, Ph.D., Vice President, R&D; Head, Oncology Research, MedImmune
Alex Yee-Chen Huang, M.D., Ph.D., Associate Professor, Pediatrics, Pathology & Biomedical Engineering, Case Western Reserve University School of Medicine
Ella Ioffe, Ph.D., Associate Director, Immune-Oncology, Regeneron Pharmaceuticals
Pushpa Jayaraman, Ph.D., Investigator II, Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research
Suchit Jhunjhunwala, Ph.D., Scientist, Bioinformatics, Genentech
Frank R. Jones, Ph.D., Chairman & CEO, Etubics Corporation
Jennifer C. Jones, M.D., Ph.D., Assistant Clinical Investigator, Molecular Immunogenetics & Vaccine Research Section, Vaccine Branch, National Cancer Institute, National Institutes of Health
Karin Jooss, Ph.D., CSO, Gritstone Oncology
Pawel Kalinski, M.D., Ph.D., Professor, Surgery, Immunology, and Bioengineering, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute
Cris Kamperschroer, Ph.D., Associate Research Fellow, Drug Safety R&D, Pfizer
Vassiliki Karantza, M.D., Ph.D., Senior Director, Clinical Research Oncology, Merck Research Laboratories
Noriyuki Kasahara, M.D., Ph.D., Professor, Departments of Cell Biology and Pathology, Co-Leader, Viral Oncology Program, University of Miami
David Kaufman, Ph.D., Executive Director, Clinical Oncology, Merck Research Laboratories
Howard L. Kaufman, M.D., FACS, Associate Director, Clinical Sciences, Rutgers Cancer Institute of New Jersey; Professor and Chief, Division of Surgical Oncology, Rutgers Robert Wood Johnson Medical School
Llew Keltner, M.D., Ph.D., CEO, EPISTAT
Arthur M. Krieg, M.D. CEO, Checkmate Pharmaceuticals
David Kirn, M.D., CEO & Co-Founder, 4D Molecular Therapeutics; Adjunct Professor, Bioengineering, University of California, Berkeley
Keith L. Knutson, Ph.D., Professor, Immunology, Mayo Clinic
David M. Kranz, Ph.D., Phillip A. Sharp Professor of Biochemistry, University of Illinois
Arthur M. Krieg, M.D. CEO, Checkmate Pharmaceuticals
Kyle Landgraf, Ph.D., Senior Scientist, Discovery Research, AvidBiotics
Jane Lebkowski, Ph.D., President & CSO, Research and Development, Asterias Biotherapeutics
Michael Lim, M.D., Associate Professor, Neurosurgery, Oncology and Radiation Oncology, Johns Hopkins University School of Medicine
Douglas Linn, Ph.D., Senior Scientist, In Vivo Pharmacology, Merck
Konstantin M. Linnik, Ph.D., Partner, Intellectual Property, Nutter, McClennen & Fish, LLP
Jason J. Luke, M.D., FACP, Assistant Professor, Medicine, Melanoma and Developmental Therapeutics Clinics, University of Chicago Medical Center
Ravi Madan, M.D., Clinical Director, Genitourinary Malignancies, Branch, National Cancer Institute, National Institutes of Health
Jennifer Mataraza, Ph.D., Senior Investigator, Immune Oncology, Novartis Institutes for BioMedical Research
Patricia McCoon, Ph.D., Principal Scientist, Oncology IMED Translational Science, AstraZeneca Pharmaceuticals
Miriam Merad, M.D., Ph.D., Chair, Cancer Immunology, Oncological Sciences, Tisch Cancer Institute, Mount Sinai Hospital
Jan ter Meulen, M.D., Dr.habil., DTM&H, CSO, Immune Design
Richard A. Morgan, Vice President, Immunotherapy, bluebird bio
Spyro Mousses, Ph.D., President, Systems Imagination Inc.
Matthew Mulvey, Ph.D., CEO, BeneVir
Kuldeep Neote, Ph.D., Senior Director, New Ventures, J&J Innovation Center Boston
Cokey Nguyen, Ph.D., Vice President, R&D, Enumeral
Fares Nigim, M.D., Massachusetts General Hospital
Patrick Alexander Ott, M.D., Ph.D., Assistant Professor, Medicine, Dana-Farber Cancer Institute
Michael J. Overman, M.D., Associate Professor, Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center
Joseph Pearlberg, M.D., Ph.D., Senior Medical Director, Infinity Pharmaceuticals
Rodney Prell, Ph.D., DABT, Principal Scientist/Toxicologist, Safety Assessment, Genentech
Maire Quigley, Ph.D., Research Investigator, Cell Process Development, Cell & Gene Therapies, Novartis
Laszlo Radvanyi, Ph.D., Senior Vice President; Head of Immuno-Oncology Translational Innovation Platform (TIP), EMD Serono
Sheila Ranganath, Ph.D., Associate Director, R&D, Enumeral Biomedical Corporation
Paul Rennert, Ph.D., President & CSO, Aleta Biotherapeutics Inc.
Aaron Ring, M.D., Ph.D., Assistant Professor, Immunobiology, Yale University School of Medicine
Scott Rodig, M.D., Ph.D., Associate Professor, Pathology, Harvard Medical School; Associate Pathologist, Pathology, Brigham & Women’s Hospital
Arjan Roozen, Vice President, GMP Solutions & Manufacturing, Cellectis
Michael Rosenzweig, Ph.D., Executive Director, Biology-Discovery, IMR Early, Discovery, Merck Research Laboratories
Stephen J. Russell, M.D, Ph.D., Professor, Mayo Clinic
Catherine Sabatos-Peyton, Ph.D., Senior Investigator, Novartis Institutes for BioMedical Research
Christian Schmees, Ph.D., Head of Tumor Biology, Molecular Biology Department, NMI Natural and Medical Sciences Institute at the University of Tübingen
Taylor Schreiber, M.D., Ph.D., CSO, Heat Biologics, Inc.
Armon Sharei, Ph.D., CEO, SQZ Biotechnologies
Michail Sitkovsky, Ph.D., Professor, Eleanor W. Black Chair, and Director, New England Inflammation and Tissue Protection Institute, Northeastern University
Craig L. Slingluff, Jr., M.D., Joseph Helms Farrow Professor of Surgery; Vice-Chair for Research; Director, Human Immune Therapy Center, University of Virginia School of Medicine
Susan R. Slovin, M.D., Ph.D., Medical Oncologist, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center
Elena Spanjaard, Ph.D., Director, Worldwide Research & Development, Regulatory Affairs, Pfizer
David M. Spencer, Ph.D., CSO, Bellicum Pharmaceuticals
Pramod K. Srivastava, Ph.D., M.D., Professor, Immunology and Medicine, Director, Carole and Ray Neag Comprehensive Cancer Center, University of Connecticut School of Medicine
Zhen Su, M.D., MBA, Senior Vice President, Global Head of Medical Affairs Oncology, EMD Serono
Brad Thompson, Ph.D., CEO, Oncolytics Biotech
Stephen Thorne, Ph.D., Professor and Scientific Advisor, Inventor, Western Oncolytics
Wolfgang Uckert, Associate Professor, Department of Cell Biology and Gene Therapy, Humboldt University Berlin
Marit van Buuren, Ph.D., Scientist, Immunology, Neon Therapeutics
Andrea van Elsas, Ph.D., CSO, Aduro Biotech Europe, The Netherlands
Janaki Veeraraghavan, Ph.D., Biologist, Office of In Vitro Diagnostics and Radiological Health, Center for Devices and Radiological Health, FDA
Luis M. Vence, Ph.D., Scientific Manager, Immunology, MD Anderson Cancer Center
Alena Gros Vidal, Ph.D., Research Fellow, Surgery Branch, National Cancer Institute
Antti Vuolanto, Ph.D., Executive Vice President, Targovax
Jeffrey Wallin, Ph.D., Group Leader, Early Stage Oncology Biomarker Development, Genentech
Steffen Walter, Ph.D., CSO, Immatics Biotechnologies GmbH
Chan Whiting, Ph.D., Director, Immune Monitoring/Biomarker Development, Aduro Biotech
Jon Wigginton, M.D., CMO & Senior Vice President, Clinical Development, MacroGenics
Andy Williams, Ph.D., Companion Diagnostics Group Leader, Cancer Immune Therapies, Genentech
Daniel Williams, Head, UK Research Operations, Adaptimmune
K. Dane Wittrup, Ph.D., Carbon P. Dubbs Professor, Chemical Engineering and Biological Engineering, Massachusetts Institute of Technology
James E. Wooldridge, M.D., CSO, Immuno-Oncology Clinical Development, Eli Lilly and Company
John Wrangle, M.D., Assistant Professor, Medicine, Hematology/Oncology, Medical University of South Carolina
Jianda Yuan, M.D., Ph.D., Director, Translational Immuno-Oncology Research, Merck Research Labs
Jonathan Zalevsky, Ph.D., Vice President, Biology & Preclinical Development, Nektar Therapeutics
Xingxing Zang, Ph.D., Associate Professor, Microbiology and Immunology & Medicine, Albert Einstein College of Medicine